IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10881666 B1

PDFFull Text
Date of Patent:
Jan. 05, 2021

Filed:

Sep. 28, 2018

Combination pharmaceutical agents as rsv inhibitors

Applicant:

Enanta Pharmaceuticals, Inc., Watertown, MA (US);

Inventors:

Brian C. Shook, Holliston, MA (US);

In Jong Kim, Lexington, MA (US);

Thomas P. Blaisdell, Brighton, MA (US);

Jianming Yu, Plainsboro, NJ (US);

Joseph Panarese, Malden, MA (US);

Kai Lin, Belmont, MA (US);

Michael H. J. Rhodin, Stow, MA (US);

Nicole V. McAllister, Groton, MA (US);

Yat Sun Or, Watertown, MA (US);

Assignee:

ENANTA PHARMACEUTICALS, INC., Watertown, MA (US);

Attorneys:

Edgar W. Harlan

Carolyn S. Elmore

Elmore Patent Law Group, P.C.

Primary Examiner:

Yong L Chu

Int. Cl.
CPC ...
A61K 31/5513 (2006.01); A61P 31/14 (2006.01); C07D 491/04 (2006.01); C07D 213/12 (2006.01); C07D 213/14 (2006.01); A61K 31/7056 (2006.01); A61K 39/42 (2006.01); A61K 39/395 (2006.01); C07D 403/12 (2006.01); C07K 16/10 (2006.01); C07D 217/14 (2006.01); C07D 243/24 (2006.01); A61K 45/06 (2006.01); C07D 217/12 (2006.01); A61K 31/4439 (2006.01); C07D 498/08 (2006.01);
U.S. Cl.
CPC ...
A61K 31/5513 (2013.01); A61K 31/4439 (2013.01); A61K 31/7056 (2013.01); A61K 39/395 (2013.01); A61K 39/42 (2013.01); A61K 45/06 (2013.01); A61P 31/14 (2018.01); C07D 213/12 (2013.01); C07D 213/14 (2013.01); C07D 217/12 (2013.01); C07D 217/14 (2013.01); C07D 243/24 (2013.01); C07D 403/12 (2013.01); C07D 491/04 (2013.01); C07D 498/08 (2013.01); C07K 16/1027 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01);
Abstract

The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.

Find Patent Forward Citations

Loading…